MICHAEL OCAMPO: Open Payments
NPI 1265782528 · LAKEWOOD, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$924 in 41 payments from 11 companies in 2025. Trend: 2023 $313 · 2024 $551 · 2025 $924
Food & beverage: $924
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 10 | $291 |
| Organogenesis Inc. | 9 | $172 |
| Amgen Inc. | 9 | $167 |
| Lilly USA, LLC | 3 | $71 |
| Exact Sciences Corporation | 3 | $63 |
| Novo Nordisk Inc | 2 | $36 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $31 |
| AstraZeneca Pharmaceuticals LP | 1 | $28 |
| Paratek Pharmaceuticals, Inc. | 1 | $22 |
| Merck Sharp & Dohme LLC | 1 | $22 |
Products named: NUCALA, CYGNUS DUAL, OTEZLA, VIA MATRIX, Cologuard Collection Kit, KRYSTEXXA, JARDIANCE, Repatha.
Industry payments across CA — which companies pay providers there.
